The popularity of Sildenafil initially drove a boom for pharma, however recent shifts present a complicated scenario for investors. Generic versions are eating into earnings, and continued litigation add more risk to https://nicolevqvr581327.actoblog.com/42088665/viagra-and-pharma-a-precarious-investment